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Ataxia Telangiectasia Mutated protein kinase (ATM) has recently come to the fore as a regulatory protein fulfilling many roles in
the fine balancing act of metabolic homeostasis. Best known for its role as a transducer of DNA damage repair, the activity of ATM
in the cytosol is enjoying increasing attention, where it plays a central role in general cellular recycling (macroautophagy) as well as
the targeted clearance (selective autophagy) of damaged mitochondria and peroxisomes in response to oxidative stress,
independently of the DNA damage response. The importance of ATM activation by oxidative stress has also recently been
highlighted in the clearance of protein aggregates, where the expression of a functional ATM construct that cannot be activated
by oxidative stress resulted in widespread accumulation of protein aggregates. This review will discuss the role of ATM in
general autophagy, mitophagy, and pexophagy as well as aggrephagy and crosstalk between oxidative stress as an activator of
ATM and its potential role as a master regulator of these processes.
1. Introduction
Ataxia Telangiectasia Mutated protein kinase (ATM) derives
its name from the severe, recessive autosomal disease Ataxia-
Telangiectasia (A-T). Although this neurodegenerative
disease was initially identified in 1926 [1] and described as
a clinical entity in 1958 [2], the gene and protein responsible
for the disease were only characterized in the early 90’s [3–5].
Null mutations in the Atm gene that cause the loss of func-
tional ATM, a 370 kDa protein, results in severe characteris-
tic cerebral ataxia and dilated blood vessels present in the
conjunctivae of the eyes, also known as telangiectasia [6].
Moreover, nonfunctional ATM has been associated with an
increased risk for cancer, radiation sensitivity, endocrine
disruption, progressive neurodegeneration, premature
ageing, and chromosomal instability (most recently reviewed
by Shiloh [7]). The degree of disease severity is dependent on
the type of mutation in the Atm gene (single or bi-allelic) and
heterozygous patients, which make up as much as 1.4-2% of
the general population, also exhibit a high incidence of isch-
aemic heart disease and insulin resistance [8, 9].
Constant oxidative stress is a common denominator in
many of the A-T clinical and cellular phenotypes [10]. The
loss of functional ATM results in prolonged activation of
stress response pathways in the cerebellum but not in the
cerebrum or liver [11]. More importantly, this suggests a
cytoplasmic role for ATM. The protein resides predomi-
nantly in the nucleus of dividing cells [12], where it acts as
a transducer in the DNA damage response pathway (DDR),
but ATM is mainly found in the cytoplasm of nondividing
neuronal cells where it maintains basal metabolic flux [13].
In these cell types, ATM maintains autophagy, a catabolic
process that delivers cytoplasmic components for degrada-
tion to the lysosome, as well as redox homeostasis, rather
than genomic stability and apoptosis. Moreover, it has been
suggested that these divergent pathways could be a result of
ATM’s subcellular localization, as well as different mecha-
nisms of activation and cell survival outcomes [13]. The
seminal study of Guo et al. [14] demonstrated for the first
time that ATM can be activated in the cytosol in response
to exogenous hydrogen peroxide (H₂O₂) independently of
DNA damage response, through the formation of a reversible
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disulphide bond at the only cysteine site within the protein
kinase domain, Cys2991. Low levels of ROS are sufficient to
activate ATM at this residue, independently of the DNAdam-
age response pathway [15], and these distinct activation
mechanisms allow ATM to respond to different stresses as
well as control different cytoplasmic pathways [16]. More
recently, studies showed that ATM can be activated by endog-
enous ROS including peroxisomal reactive oxygen species
(ROS) induced by clofibrate treatment [17] and mitochon-
drial superoxide induced by low doses of the redox-cycling
chemical, menadione [18]. Both peroxisomal and mitochon-
drial ROS activation of ATM increase autophagy through
the activation of AMPK that results in mTOR suppression
in the cytosol [19]. Taken together, this suggests that ATM
can directly modulate the rate of autophagy in a ROS depen-
dent manner [20] and will be discussed in further detail.
ATM acts as an important sensor of oxidative stress in
cells and regulates defences against redox stress [14] by
rerouting of glycolysis to the pentose phosphate pathway
(PPP) [21] (reviewed more extensively by Blignaut [22]).
ATM also regulates mitochondrial biogenesis and DNA con-
tent [23] and can lead to mitochondrial dysfunction when
absent [24, 25]. Antioxidative treatment that targets the
mitochondria in the absence of ATM can decrease the meta-
bolic syndrome, which supports the notion that A-T might
be a mitochondrial disease [26, 27]. Importantly, ATM also
contributes to glucose homeostasis [28] and is required for
the phosphorylation of the insulin-dependent protein kinase,
Akt [29, 30].
This review will focus on crosstalk between ROS as an
activator of ATM and autophagy as a regulatory mechanism
of protein aggregation and oxidative stress in the context of
nondividing cells.
2. ATM and Oxidative Stress
ATM is a relatively large protein of 370 kDA, consists of
approximately 3056 residues and is part of the PI-3 kinase-
like protein kinase (PIKKs) family [31]. The catalytic func-
tion of ATM identifies with the mechanisms mostly found
in serine-threonine proteins that phosphorylate downstream
proteins on the hydroxyl group of the serine or threonine
residues [32].
The most common function of ATM is to respond to
double strand DNA breaks in the nucleus, where the protein
is autophosphorylated at Ser1996, followed by monomeriza-
tion of the dimer, and activated in response to DNA damage
[33–35]. Upon activation, ATM is responsible for the phos-
phorylation and activation of downstream proteins, includ-
ing the Mre11, Rad50, and Nbs1 complex (MRN complex),
which aid in DNA repair [35].
Alternatively, ATM can be activated in response to oxida-
tive stress and hypoxic conditions [36, 37], but the question
remained whether this can be achieved independently of
the DDR pathway. This was answered in a groundbreaking
study that reported the direct activation of ATM by hydrogen
peroxide (H2O2) as an inducer of oxidative stress [14]. This
study investigated ATM activation under oxidative stress
conditions generated with H2O2 and double strand DNA
breaks (DSBs) with bleomycin, a well-known genotoxic
agent, in human fibroblasts. Although p53 was phosphory-
lated at Ser15 and Thr68 in response to H2O2 and bleomycin,
in an ATM-specific manner, the histone variant, H2AX, as a
marker of DNA repair, was only phosphorylated in response
to the latter treatment. Inhibition of ATM ablated the
phosphorylation of the DNA damage-specific proteins p53,
ATM, and Chk2 in the presence of H2O2, whilst activation
of ATM by H2O2 was inhibited in the presence of the strong
hydroxyl scavenger, N-acetylcysteine (NAC). They reported
that oxidation resulted in a conformational change in ATM
but not the monomerization observed in response to DNA
damage. The study found that ATM forms a reversible
disulphide bond at the cysteine site, Cys2991, and mutation
of this site from Cys2991 to Ala2991, resulted in a construct
that can be activated in the presence of DSBs but not oxida-
tive stress. Although ATM contains several disulphide bonds,
it is the covalent disulphide bond at Cys2991 through which
ROS modulates its effects.
However, it should be noted that the interplay between
oxidized ATM and DSB-activated ATM is complicated:
Guo et al. [14] suggested that oxidative stress disrupts DNA
binding at the complex responsible for ATM recruitment to
the damaged site and can therefore inhibit ATM activation
by DSBs, resulting in the oxidation of ATM under high
ROS conditions. A more recent study showed that excess
endogenous ROS represses ATM-dependent homologous
DNA repair in cells obtained from ataxia patients with oculo-
motor apraxia type 3 (AOA3 cells) which has implications
for both neurodegeneration and tumorigenesis [38]. Irre-
spective of the lack of consensus with regard to the oxidation
of ATM under either high or low ROS conditions, many of
the ATM substrates identified with proteomic analyses,
implicate ATM in metabolic signalling pathways [39].
Under normal physiological conditions, ROS act as
signalling intermediates in many cellular processes to induce
redox homeostasis. On the other hand, elevated ROS levels,
aptly described as oxidative stress, have been linked with over
150 diseases, most notably atherosclerosis, diabetes, and
cancer [19]. It has therefore been suggested that A-T might,
in essence, be an oxidative stress disorder [40]. In order to
understand how ATM contributes towards the maintenance
of basal metabolic flux and redox homeostasis, a short over-
view of oxidants and their cellular targets is required.
Briefly, ROS derive from the reduction of molecular oxy-
gen which most notably includes oxygen (O2
•-), hydroxyl
(•OH), peroxyl (RO2•), and alkoxyl (RO•), as well as certain
nonradicals that are either oxidizing agents or can be con-
verted into radicals such as hypochlorous acid (HOCl), ozone
(O3), single oxygen (ᶦO2), and H2O2 [41]. Metabolism of
nitric oxide (NO) results in the formation of reactive nitro-
gen species (RNS) that can either contribute to oxidation,
nitrosation, or nitration [42]. The enzymatic action of nitric
oxide synthase (NOS) results in the formation of nitric oxide
(NO) but can also produce O2
•- under the right circum-
stances. A rapid reaction between NO and O2
•- results in
the formation of peroxynitrite (ONOOH) which is involved
in oxidation, nitrosation, and nitration. In the case of nitra-
tion, nitrotyrosine can be formed and alter cell signalling
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pathways. For example, nitrite together with HOCl has been
detected in diseased human vascular tissue and drives the
formation of artherogenic LDL which is implicated in athero-
sclerosis [43].
There are numerous sources of endogenous ROS includ-
ing the cytoplasm, where O2
•-, generated by either mitochon-
dria or the NOX-family (nicotinamide adenine dinucleotide
phosphate (NADPH) oxidases), is converted to H2O2, as well
as the production of H2O2 by the endoplasmic reticulum
(ER) as a byproduct of protein oxidation and as an end prod-
uct in several peroxisomal oxidation pathways including β-
oxidation of long-chain fatty acids [44, 45]. NOX1, -2, -4,
and -5 transport electrons across biological membranes in
order to reduce oxygen to superoxide and are expressed
throughout the cardiovascular system, brain, and cerebrovas-
cular tissue (extensively reviewed by [41]). This protein fam-
ily is one of the best known sources of cytoplasmic ROS,
which in itself has been described as the cornerstone of cellu-
lar signalling and disease pathophysiology [46–48]. The
broad impact of ROS is made possible by the large number
of molecules that ROS can interact with, including small
organic molecules, proteins, lipids, carbohydrates, and
nucleic acids. These interactions can either destroy or irre-
versibly change the function of the target molecule and
accordingly contribute towards pathogenesis [41].
Most redox reactions, however, occur through the
reversible reduction and oxidation of crucial reactive cyste-
ine residues that form thiolate anions at a physiological
pH [49]. Oxidation of this residue, as is the case for ATM
at Cys2991, results in a sulfenic residue (SOH), which is
further modified to form an intramolecular disulphide
bond. As mentioned previously, the addition of exogenous
H2O2in vitro forms an active ATM dimer of two
covalently-linked monomers. Possible in vivo sources of
oxidants, that can reduce thiol and oxidizing disulphide
bonds, are generated by the membrane bound NOX-family
of NADPH oxidases. These enzymes produce anions that
can be dismutated into H2O2 which selectively re-enters
the cell through aquaporin channels [44].
NOX-4, which is located in close proximity of the nucleus
in a wide range of human cells, produces ROS innately and is
elevated in A-T cells [50]. Specific inhibition of both NOX-4
and NOX-2 alleviates increased cancer risk in A-T null mice,
whilst the inhibition of ATM increased NOX-4 expression in
normal cells. NOX-4 is thus potentially a critical mediator of
ROS and in the development of A-T.
Most recently, Zhang et al. [18] reported that ATM acts
as a redox-sensor in response to endogenous mitochondrial
ROS (H2O2) and serves as a critical juncture in the regulation
of carbohydrate metabolism. The study showed that glutathi-
one production, which is also an endogenous antioxidant, is
increased in cells expressing an ATM Cys2291Ala mutant
construct and suggests that this is an attempt to compensate
for a lower glucose flux through the PPP, thus decreasing the
availability of NADPH.
Taken together, ATM can be activated in response to
exogenous (H2O2) and endogenous ROS (mitochondrial) as
well as through NADPH-oxidases, allowing it to respond as
a redox-sensor for the PPP [16]. However, ATM has also
been shown to mediate autophagy in response to oxidative
stress, which will be discussed in the following section.
3. ATM-Mediated Autophagy
Autophagy is a highly regulated catabolic process that liter-
ally translates to “self-eating”; this general term describes
the delivery of cytoplasmic components, including parts of
the cytosol and large protein complexes, within a double
membrane vesicle (autophagosome) to the lysosome for deg-
radation [51]. Basal physiological autophagy ensures cellular
homeostasis and protein recycling within all eukaryotic cells
[52] but can also be stimulated in response to cellular stress,
including but not limited to, oxidative stress, hypoxia, nutri-
ent starvation, DNA damage, and protein aggregation [53].
The ubiquitin-proteosome system (UPS) targets only individ-
ual, short lived, or misfolded proteins for degradation, whilst
autophagy recycles larger components such as damaged
organelles, excessive, or toxic byproducts and larger protein
complexes and aggregates [54]. This diverse but specific deg-
radation response is enabled by three types of autophagy,
namely, macroautophagy, microautophagy, and chaperone-
mediated autophagy, which differ with regard to their targeted
substrate and sequestration mechanism [55]. This review will
focus on the role of ATM in ROS-induced macroautophagy.
The initiation of macroautophagy occurs in the cyto-
plasm via the activation of adenosine 5′-monophosphate-
(AMP-) activated protein kinase (AMPK) in response to
nutrient starvation and hypoxia [56]. Moreover, AMPK acti-
vation results in the inhibition of lipid and glycogen synthe-
sis, whilst concurrently activating free fatty acid oxidation
and glycolysis [56]. Moreover, the activation of AMPK phos-
phorylates and activates TSC2 (tuberous sclerosis complex 2)
resulting in the repression of mTOR complex 1 (mechanistic
target of rapamycin complex 1), which is a negative regulator
of autophagy [57]. AMPK activation can also phosphorylate
the mTOR-binding partner, raptor, and induces 14-3-3 bind-
ing to raptor, which is required for the inhibition of
mTORC1 [58], as well as phosphorylate mTORC1 directly
at Thr2446 [59]. Once mTORC1 is repressed, unc-51-like
kinase (ULK1) is dephosphorylated and consequently acti-
vated. Under starvation conditions, AMPK promotes
autophagy through the direct phosphorylation of ULK1 at
Ser317 and Ser777, whereas sufficient nutrients promote
mTOR activity and prevents ULK1 activation through phos-
phorylation at Ser757, consequently disrupting the interaction
between ULK1 and AMPK [60]. ULK1, together with Atg1,
form one of at least five core molecular components that is
required for the formation of the autophagosome membrane
[61]. The other core molecular components include the
Beclin1/class III PI3K complex; the transmembrane proteins,
Atg9 and vacuole membrane protein 1 (VMP1); and two
ubiquitin-like protein conjugation systems, Atg12 and
Atg8/LC3 [62]. Once the formation of a phagophore is
initiated, the vesicle expands sequentially and engulfs the
cytosolic cargo, in either a selective or nonselective manner,
to form the autophagosome [63]. The formation of the
autophagosome is driven by the Atg (AuTophagy related)
proteins and has been reviewed extensively [63, 64].
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Selectivity of the targeted cargo is conferred by recep-
tors that recognize and interact with lipidated ATG8 family
proteins, which are located on the concave side of the
developing autophagosome [65]. This interaction is enabled
by LC3 interacting regions (LIR) that bind to the LIR dock-
ing sites of ATG8 family proteins [65]. The ATG8 family
consists of the LC3/GABARAP protein family and includes
the microtubule-associated protein 1 light chain 3
(MAP1LC3A-B and C) or γ-aminobutyric acid (GABA) type
A receptor–associated protein (GABARAP and GABARAP-
like 1 and -2) [66]. Of these proteins, the best-studied protein
is LC3B, which confers selectivity, together with the
GABARAP proteins, for pexophagy and mitophagy through
interaction with adapter proteins [66]. LC3B associates with
the forming autophagosomal membrane through the forma-
tion of a covalent bond to phosphatidylethanol (PE) enabled
by a ubiquitination-like sequence of enzymatic events where
ATG7 acts as the LC3 activating enzyme and ATG 3 as the
conjugating enzyme that transfer LC3 to PE to form lipidated
LC3-PE/LC3-II [67, 68].
Autophagy adapter proteins interact directly with the
ATG8 proteins and share the ability to interact simulta-
neously with the autophagosome through interaction of their
LIR motif with LC3 as well as the cargo substrate, which is
often ubiquitylated [67]. These receptors include, amongst
others, p62/SQSTM1, BNIP3 (BCL2/adenovirus E1B
19 kDa interacting protein), FUNDC1 (Fun14 domain con-
taining 1), NBR1 (neighbour of BRCA1), NDP52 (nuclear
dot protein of 52 kDa), and optineuron, of which many have
a ubiquitin-binding domain (UBD) that can interact with
different ubiquitin chain linkages associated with the targeted
cargo and in doing so, provide selectivity [67]. Once the
cargo is tethered to the forming autophagosome, LC3B and
the GABARAP subfamily promote the elongation and fusion
(closure) of the autophagosome [66], which can then fuse
with the lysosome to form an autolysosome and results in
pH changes to occur in the lumen of the lysosome [69].
The change in lysosomal pH is essential for successful protein
degradation as the hydrolyses responsible for cargo break-
down are activated in an acidic environment [70]. The
process of autophagosome maturation, trafficking, and lyso-
somal fusion as well as the proteins involved in this process
has recently been reviewed extensively [71].
In view of the oxidative stress induced activation of ATM,
as well as the pathophysiology associated with elevated ROS
in ATM-deficient cells, Alexander et al. [19] reported that
the activation of oxidized ATM increases autophagy through
the activation of TSC2 via the liver kinase B1 (LKB1)/AMPK
pathway, resulting in the repression of mTORC1. Moreover,
inhibition of mTORC1 with rapamycin results in the con-
comitant improvement of ROS levels in ATM-/- mice. The
authors found that low concentrations of H2O2 rapidly
induced mTORC1 repression that could, in turn, be rescued
by the addition of NAC or pretreatment with catalase. Of
relevance as well, is that chemical mitochondrial uncou-
pling which depletes the antioxidant, glutathione, also
repressed mTORC1 signalling, indicating that both exoge-
nous and endogenous ROS activation of ATM can induce
mTORC1 repression.
The same research group found that nitrosative stress
(nitric oxide (NO)) also activates ATM and results in the
phosphorylation of AMPK through LKB1, activation of the
TSC2 complex and consequent repression of mTORC1
[72]. ATM-mediated repression of mTORC1 decreased
phosphorylation of direct target proteins of mTORC1 such
as 4E-BP1 (4E-binding protein 1), S6K (ribosomal S6
kinase), and ULK1 (Unc-51 like autophagy activating
kinase). Consequently, nitrosative stress-mediated activation
of ATM can increase autophagy by decreasing mTORC1
mediated phosphorylation of ULK1 at Ser757 and increasing
ULK1-phosphorylation at Ser317 by AMPK. However, the
precise mechanism through which NO activates ATM is still
unknown. Induction of autophagy by NO also resulted in
decreased cell viability, which suggests a cytotoxic response.
LKB1 can be phosphorylated directly at Thr366 by active
ATM in response to ionising radiation (IR) [73] as well as
through oxidative stress as discussed above, consequently
activating AMPK directly to modulate apoptosis [74] or
autophagy in the event of energetic stress.
On the other hand, one of the key roles of AMPK in
cardiac tissue is the response to hypoxia/ischaemia, which
is also under the direct control of LKB1; in the absence of
LKB1, mouse hearts show increased mTORC1 signalling
and protein synthesis that can lead to hypertrophy [75].
Interestingly, Emerling et al. [76] showed that the hypoxic
activation of AMPK in mouse fibroblasts is dependent on
mitochondrial oxidative stress that is generated by the ETC
and not the cytosolic adenosine monophosphate (AMP)/ade-
nosine triphosphate (ATP) ratio. Although they did not eval-
uate the role of ATM in their study, it supports the notion
that the oxidative activation of ATM, due to increased mito-
chondrial dysfunction, can potentially mediate the activation
of AMPK in response to hypoxic stress.
In a nutshell, autophagy is a catabolic process responsible
for the degradation and recycling of damaged organelles and
is central to the maintenance of cellular homeostasis. The
activation of ATM through ROS and NO places ATM
directly upstream of AMPK, which in turn, drives the inhibi-
tion of mTORC1 and upregulation of autophagy through
ULK1. This allows cells to eliminate damaged organelles that
can drive increased oxidative stress and recycle these compo-
nents to maintain nutrient and energy homeostasis, but this
process can also be mediated independently of ATM. ROS-
induced autophagy can be induced by either O2
•- [77] or
H2O2 [78] that is produced in response to either glucose or
nutrient starvation and can cause mitochondrial energetic
stress due to decreased ATP availability [52]. Both redox
balance and ROS formation can be regulated by changes in
the autophagy rate and consequently either directly regulate
mitochondrial homeostasis or indirectly regulate mitochon-
drial function [79].
Key to effective autophagy, which is also responsible for
the degradation of ATM [80], is the fusion of the autophago-
some to lysosomes, in order to form an autolysosome where
the targeted content is degraded. Recent observations in
ATM-/- neurons showed upregulated autophagic flux of
lysosomes with a more acidic pH and led to the finding that
the ATPase, H+ transporting lysosomal V1 subunit A
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(ATP6V1A proton pump) is a target of ATM [80]. The
absence of ATM results in the peri-nuclear accumulation of
lysosomes which suggests that this could be due to a physical
interaction between ATM and the retrograde transport
motor protein, dynein. Lysosomal dynein accumulates in
ATM -/- mouse brains indicating that ATM inhibits axonal
transport through dynein motor proteins. Similarly, the
study found that the loss of ATM resulted in the impaired
glucose uptake due to the inhibition of the translocation
of the SLC2A4/GLUT4 (solute carrier family 4 (facilitated
glucose transporter) 4) to the plasma membrane, and
increased trafficking to lysosomes instead [80]. This obser-
vation further supports previous reports that decreased
ATM activity is associated with metabolic syndrome [81]
and insulin resistance [82]. The importance of ATM in
autophagy is highlighted by the accumulation of lysosomes,
as well as increased oxidative stress in the cerebellum of
ATM-null mice [83].
Increased oxidative stress and a weakened antioxidant
defence due to dysfunctional autophagy can induce cellular
damage and result in neuronal cell death, which is the major
causative factor in the development of Parkinson’s disease,
which predominantly affects aged individuals above 60
[71]. Increasing age results in a decline in autophagy as well
as an increase in protein misfolding and oxidative stress
[67] and can lead to the disruption of cellular homeostasis
[68]. Similarly, age-associated decreases in ATM protein
levels [84] may result in the development of metabolic syn-
drome, lysosomal accumulation, and protein aggregation
that are associated with age-related neuronal diseases [85]
and the development of cardiac dysfunction including fibro-
sis and hypertrophy [86].
4. ATM and Aggrephagy
Protein aggregates develop when proteins are misfolded due
to mutations, incomplete translation, inappropriate protein
modifications, oxidative stress, and ineffective assembly of
protein complexes [87]. The accumulation of misfolded and
dysfunctional protein aggregates, often due to oxidative
stress [88, 89] or downregulated or disrupted autophagy
[90], can be toxic to the cell and cause a disruption of cellular
homeostasis that is detrimental to cellular survival in many
diseases, and in particular, neurodegenerative diseases [91].
Aggregation is driven by exposed hydrophobic patches in
misfolded proteins that sequester other proteins. Misfolding
can be repaired by molecular chaperones, but if the damage
is too great, the misfolded proteins are guided by chaperone
complexes for degradation by either the ubiquitin-
proteosome system (UPS) or the lysosome through chaper-
one mediated autophagy or aggrephagy [87]. The latter
process specifically refers to the selective sequestration of
protein aggregates by macroautophagy and will be the
discussed further.
Protein aggregation is classically associated with neuro-
degeneration but has been observed in nearly every cardio-
metabolic disease [92]. The accumulation of proteins and
dysfunctional organelles contributes to the development of
pathology in almost all tissues and thus requires a very fine
balance between apoptosis and autophagy [93]. There seems
to be synergistic roles for ATM and p53 with regard to the
regulation of autophagy, where ATM regulates mitochon-
drial homeostasis and oxidative stress in order to prevent
cells from undergoing apoptosis in response to nongenotoxic
p53 activation [94]. Genetic or pharmacological loss of ATM
kinase activity blocks autophagy and increases ROS, which is
sufficient to commit cells to apoptosis in response to Nutlin 3
treatment, an inhibitor of the p53 E3 ubiquitin ligase MDM2
that activates p53 [94].
Most recently, it has been shown that the loss of function
mutation that blocks ATM activation by oxidative stress, but
not genotoxic stress, results in widespread protein aggrega-
tion, especially when cells are exposed to low levels of ROS,
and includes polypeptides mainly implicated in DNAmetab-
olism and gene expression [95]. This implicates a role for
ATM in protein homeostasis. Moreover, protein aggregation
is very relevant to neurodegeneration, especially with regard
to the loss of function of Purkinje neuronal cells, which is a
hallmark of A-T [96].
Proteasomal degradation is also required for the mainte-
nance of autophagy at physiological levels as is the case with
ULK1; it is specifically ubiquitinated by the E3 ligase
NEDD44 that marks it for proteasomal degradation, whilst
still being actively translated and transcribed [75]. The tran-
scription of ULK1 is in turn inhibited by mTOR during pro-
longed autophagy and allows for the maintenance of ULK1
protein at basal levels within the cell.
It is also possible that ATM can play a more active role in
ULK1 phosphorylation through p32. Although p32 was first
recognized as a novel substrate of ATM in cardiac DNA
damage [97], it has recently been identified as a regulator of
ULK1 stability [98]. In a study that investigated the cardio-
toxicity and genotoxic effect of chemotherapeutic agents that
induce cell death through the ATM-mediated phosphoryla-
tion of p53, the protein, p32 (CIQBP/HABP1), was identified
as an endogenous substrate in mouse hearts [97]. The protein
is phosphorylated at Ser148 by ATM in response to genotoxic
stress, but the authors did not comment on the physiological
effect thereof [97]. However, p32 has been found to be essen-
tial for maintaining the activity and stability of ULK1 [98].
The study found that the ablation of p32 results in increased
proteolysis of ULK1, that consequently impaired starvation-
induced autophagic flux as well as the clearance of damaged
(uncoupled) mitochondria, and highlights the importance of
p32 for ULK1 activity. The phosphorylation of ULK1 by
AMPK also regulates the translocation of ULK1 to mito-
chondria in response to hypoxia [99] where it phosphory-
lates the autophagy cargo receptor, FUNDC1 [100], and
regulates mitophagy [101]. Although ATM was not investi-
gated in this context, it is tempting to hypothesize that ATM
could influence ULK1 potentially through the phosphoryla-
tion of p32 in the heart.
5. ATM Mediates Selective Autophagy
Constitutive autophagy plays a protective role in mito-
chondrial rich cardiomyocytes, where accumulation of
abnormal proteins and organelles, especially mitochondria,
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may directly cause cardiac dysfunction [102]. Mitophagy, a
specialized mechanism of autophagy that specifically aims
to degrade and maintain mitochondrial quality, is central to
maintaining cellular integrity and cellular homeostasis
[103]. The process of mitophagy is known to decrease during
ageing, thus resulting in mitochondrial dysfunction [104].
Classically, depolarized mitochondria initiate the
accumulation of (PTEN-) induced kinase 1 (PINK1) on the
outer mitochondrial membrane [105]. PINK1 is degraded
in healthy mitochondria but accumulate on the outer mito-
chondrial membrane of damaged mitochondria that, in turn,
drives the recruitment and translocation of Parkin [85] to the
mitochondria. Parkin is an E3 ubiquitin ligase which is phos-
phorylated by PINK1, stimulating its translocation to the
mitochondria where it ubiquinates several outer mitochon-
drial membrane proteins. This promotes further PINK1
phosphorylation and the formation of ubiquitin chains that
localizes mitophagy receptors that contain UBDs to Parkin-
ubiquitylated mitochondria, including p62 (SQSTM1),
NBR1, and optineurin [106] that can attach to autophagoso-
mal membranes and envelop the damaged mitochondria
(reviewed by Nguyen et al. [107]) for degradation [108].
PINK1 also phosphorylates the fusion protein, mitofusin
2 (Mfn2), which can serve as a mitochondrial receptor for
Parkin, promoting its ubiquitination [88]. The loss of Mfn2
prevents the translocation of Parkin in depolarized
mitochondria and suppresses mitophagy, which drives the
accumulation of dysfunctional mitochondria and decreased
mitochondrial respiration in mouse cardiomyocytes [88].
Alternatively, mitophagy can be mediated by mitophagy
receptors. Mitochondrial receptor-mediated autophagy is
mediated by the pro-apoptotic proteins, BNIP3 and NIX,
that localize to the outer mitochondrial membrane and act
as receptors for targeting autophagosomes through direct
interaction of conserved LC3-interacting regions (LIRs) with
LC3 on the autophagosome, often in response to hypoxia
[109] and in the absence of mitochondrial membrane perme-
abilization [110]. FUNDCI is an outer mitochondrial mem-
brane protein that has been implicated in hypoxia-mediated
mitophagy in mammalian cells [111]. Similar to BNIP3 and
NIX, FUNDC1 acts as a receptor for the autophagosomal
membrane and interacts directly with LC3 through LIR.
The serine/threonine protein phosphatase, PGAM5, dephos-
phorylates FUNDC1 during hypoxia or mitochondrial
membrane depolarization and promotes interaction with
LC3 with consequent mitophagy [112].
More recently, a direct link between ATM and PINK1/-
Parkin recruitment was shown, as ATM was able to initiate
the accumulation of PINK1 and translocation of Parkin in
the presence of spermidine and lead (Pb) initiating mito-
phagy [113, 114]. Spermidine is a natural polyamine involved
in several biological processes including cell proliferation and
apoptosis and tends to decline with age [115]. Spermidine
also elicits mitochondrial depolarization that causes the
formation of mitophagosomes and mitochondrial targeted
lysosomes, which has been suggested to occur via ATM-
dependent activation of the PINK1/Parkin mitophagy
pathway [114]. Spermidine-induced mitochondrial depolari-
zation is abrogated in the presence of the chemical ATM
inhibitor, KU55933. Moreover, spermidine promotes the
colocalization of phosphorylated ATM and PINK1 on the
outer mitochondrial membrane, which, together with the
translocation of Parkin, can be blocked by the ATM inhib-
itor. The authors suggest a model whereby activated ATM
drives PINK1 accumulation as well as Parkin translocation
with consequent mitophagy in response to spermidine
treatment (Figure 1).
ATM may therefore be central to mitophagy by directly
activating the pathway or by indirectly activating autophagy
in response to oxidative stress. Thus, if pathological ATM
signalling occurs, mitophagy could be affected, predisposing
the cell to mitochondrial oxidative stress [22]. ATM is also
activated by nitrosative stress and contribute to sustained
mitophagy of damaged mitochondria through the newly
characterized ATM-denitrosylase S-nitrosoglutathione
reductase (GSNOR) axis [116].
The chronic oxidative stress observed in A-T has led to
the suggestion that A-T might be a mitochondrial disease
[40] and has also been linked with intrinsic mitochondrial
dysfunction [24]. The latter study found that lymphoblastoid
cells from A-T patients contain an increased population of
mitochondria with a decreased membrane potential, when
compared to control cells. Proteins with specific roles in
mitochondrial DNA damage and/or ROS scavenging,
including mnSOD, peroxiredoxin 3, and mitochondrial
topoisomerase, were also elevated in these cells. Indeed, the
decreased membrane potential translated into decreased
respiratory activity in the A-T cells compared to the wild type
controls. Concomitantly, the authors showed that the in vivo
loss of ATM in mice resulted in mitochondrial dysfunction in
thymocytes that was accompanied by increased mitochon-
drial content and mitochondrial ROS due to a decrease in
mitophagy. Interestingly, they observed a significant decrease
in complex I activity as well as ATP production and an
increase in oxygen consumption. The study also found that
autophagy was not affected by the absence of ATM and
suggested that changes in mitochondrial dynamics such as
fission and fusion could contribute towards defective mito-
phagy. The authors concluded that the observed defects in
the absence of ATM suggest that ATMmight localize directly
to mitochondria. Fractionation studies in cells revealed that
the mitochondrial fraction of HepG2 cells was enriched with
ATM and activated ATM in response to H2O2 treatment
[117]. In contrast to previous observations that ATM associ-
ated with the peroxisomal fraction [118], Morita et al. [117]
detected almost no ATM in this fraction. This reverberates
with the suggestion [119] that both the cell type and culture
conditions of immortalized A-T cells can affect mitochon-
drial homeostasis and autophagic responses which explain
the differences in mitochondrial content reported in A-T
deficient cell lines.
Mitochondrial respiration inhibition can also lead to
increased mitochondrial ROS production. Treatment of
HeLa cells with either rotenone or Antimycin C failed to
increase mitochondrial hydrogen peroxide production
although it did increase mitochondrial superoxide produc-
tion [18]. Superoxide itself failed to drive ATM dimerization
and suggested that mitochondrial superoxide must be
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converted to H2O2 in order to activate ATM in either the
cytosol or nucleus of HeLa cells.
Our group reported that ATM is directly associated
with the inner mitochondrial membrane of cardiac mito-
chondria, and the inhibition thereof decreases oxidative
phosphorylation and the ATP synthesis rate in a complex
I-mediated manner [120]. Similarly, ATM-/- thymocytes
exhibit decreased complex I activity [25], whereas the
chemical inhibition of ATM resulted in a posttranslational
decrease of COX-IV [121]. This is interesting because the
inhibition of COX-IV has been associated with increased
ROS production at complex I, albeit in the mitochondrial
matrix [122]. Depletion of ATP in neuronal Purkinje cells
results in increased ROS production that can activate ATM,
consequently leading the phosphorylation of Nrf1 that
specifically upregulates the expression of nuclear-encoded
mitochondrial genes and improves electron transport chain
capacity and restores mitochondrial function [123].
Similarly, Fang et al. [124] reported increased mitochondrial
content in ATM-knockdown (ATM-KD) rat neurons
coupled to increased ROS production. The authors suggested
that this could reflect decreased ATP production and either
inadequate or inefficient mitophagy. Moreover, the study
showed that mitophagy is suppressed in ATM-KD HeLA
cells and rat neurons but that the phenotype could be rescued
by replenishing cellular NAD+ which significantly improved
life-span in ATM-/- mice [124].
Interestingly, Beclin-1 heterozygosity in ATM-/- mice
reduces mitochondrial ROS and complex I abnormalities in
thymocytes [25]. Beclin-1 forms part of the complex required
for the induction of autophagy [125] but is also required for
the recruitment of Parkin to the mitochondrial membrane
where it induces ubiquitination and proteasomal degradation
of proteins on the outer mitochondrial membrane [126].
This leads to the inhibition of fusion and the trafficking of
dysfunctional mitochondria [126]. It is still unclear why the
allelic loss of Beclin1 would promote improvement of mito-
chondrial dysfunction in ATM-/- mice, but it has led to the
suggestion that Beclin-1 might have additional functions


























































Figure 1: ROS can activate cytosolic ATM. ATM is activated in response to both endogenous and exogenous ROS, as well as NO at Cys2991,
where it forms a disulphide bond. Once activated, it phosphorylates LKB1 at Thr366 which phosphorylates AMPK and drives the inhibition of
mTORC1 through TSC2. The inhibition of mTORC1 phosphorylates ULK1 at Ser757, whilst AMPK phosphorylates ULK1 at Ser313. This
initiates autophagy and the formation of an autophagosome that targets peroxisomes specifically for degradation through the ATM-
mediated ubiquitination of PEX5. It is currently unknown whether ATM is involved in either the activation of AMPK or suppression of
mTOR in response to ROS to induce mitophagy. ATM mediates PINK/Parkin mitophagy pathway in response to spermidine treatment,
which induces ROS and consequently activate ATM, that is then recruited to the permeabilized mitochondrial membrane where it
colocalize with PINK and drives the recruitment of Parkin which is ubiquitinated. The ubiquitin chain binds to LC3 (green balls) on the
autophagosome, which then engulfs damaged mitochondria for lysosomal degradation (not shown). Hypoxia or mitochondrial
uncoupling can also activate ULK1, driving its translocation to the damaged mitochondrion membrane where it phosphorylates FUNDC1,
which enhances its binding to LC3, whereas the dephosphorylation of FUNDC1 by PGAM5 also allows FUNDC1 to directly interact with
LC3. BNIP and NIX can act as mitochondrial receptors in response to hypoxia when the mitochondrial membrane is not permeabilized
and bind to LC3 on the autophagosome. Damaged mitochondria produce less ATP that activates AMPK, which in turn phosphorylates
ULK1 and activates the Beclin1-VSP34-VSP15 complex and drives the formation of an autophagosome. Damaged mitochondria can also
produce ROS which inhibits mTOR and leads to the activation of autophagy.
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Terminally differentiated cells such as cardiomyocytes
and neuronal cells are dependent on the efficient removal
and replacement of dysfunctional mitochondria to ensure
cell survival and to maintain cellular homeostasis [111,
127]. A decrease in ATP production and increased ROS pro-
duction as indicators of mitochondrial dysfunction can result
in either the release of apoptotic proteins or the selective
clearance of the damaged mitochondria. Mitophagy thus
serves as an early cardioprotective response through the
removal of damaged mitochondria, and if this fails, apoptosis
can be induced in response to excessive oxidative stress [128].
Moreover, reduced autophagy, together with the accumula-
tion of dysfunctional mitochondria, has been associated with
heart failure and aging [111].
Pexophagy is the targeted selective degradation of perox-
isomes [129] and is another example of selective autophagy
[130]. Peroxisomes utilise β-oxidation to reduce long-chain
fatty acids into medium length fatty acids that can be shuttled
to the mitochondria. These highly metabolic organelles
generate ROS during β-oxidation and require homeostatic
maintenance to prevent oxidative stress. ATM binds to the
peroxisome importer receptor, PEX5, in response to exces-
sive ROS and mediates peroxisome-specific autophagy
(pexophagy) by phosphorylating PEX5 at Ser141 and promot-
ing mono-ubiquitylation at Lys209, whilst simultaneously
inducing autophagy through the activation and phosphoryla-
tion of TSC2 and ULK1 [17, 131, 132]. Ubiquitylation of
PEX5 is mediated by the complex PEX2-PEX10-PEX12 and
is then recognized by the autophagy adapter proteins, p62
and NBR1, which directs the autophagosome to the peroxi-
somes for pexophagy [129].
Loss of function mutations in ATM, such as the ability to
sense oxidative stress, can result in a reduction in mitochon-
drial antioxidant defences, lead to the accumulation of ROS
and oxidative damage to mitochondria and other cellular
components [18], as well as protein aggregation [95]. Selec-
tive autophagy seems to be mainly mediated by ubiquitina-
tion which is essential for conferring selectivity [133], as is
the case of ATM-mediated pexophagy. As previously
discussed, this also implies a potential role for ATM in aggre-
phagy (degradation of damaged or misfolded proteins) which
is dependent on p62 ubiquitination [92].
6. Conclusion
This broad overview describes the apical protein, ATM
protein kinase, at the nexus of oxidative stress-induced
autophagy [14, 18] as well as nitrosative stress-induced
autophagy [72, 116], mitophagy [113, 114], and pexophagy
[17, 132] mainly in the context of nondividing cells such as
cardiomyocytes and neurons. Site-specific mutations that
renders ATM insensitive to oxidative stress increase protein
aggregation [95], whilst loss of function increases peri-
nuclear lysosomal accumulation [80] as well as mitochondrial
oxidative stress [25] and dysfunction [24, 25, 120]. Cytoplas-
mic ATM thus plays a central role in redox homeostasis and
ROS-mediated autophagy.
As a master regulator of DNA repair, activation of ATM
by exogenous and endogenous oxidative stress, indepen-
dently of DNA strand breaks, only recently came to light
[14, 18]. This finding paved the way to understanding the
severe neurodegeneration and associated protein aggregation
observed in A-T patients that is largely due to disrupted
ATM protein kinase functioning leading to disrupted
autophagy, mitophagy, and pexophagy [80, 95]. Additionally,
the regulation of ATM levels by autophagy [80] and the role of
ATM in oxidative stress-mediated autophagy in an AMPK/m-
TORC1dependentmannerwere discovered [13, 19, 132]. Sim-
ilarly, ROS-induced pexophagy is modulated by ATM
through the TSC2/AMPK/mTORC1 pathway in which the
disruption of this signalling pathway leads to interrupted cel-
lular homeostasis causing pathologies linked to neurodegen-
eration [17, 131, 134].
It has been suggested that the pathogenesis of A-T could
be ascribed to excessive ROS and that A-T might therefore be
an oxidative stress disease [40]. Several studies have investi-
gated the effect of the absence or inhibition of ATM on
mitochondrial function and found that ATM is innately
associated with the inner mitochondrial membrane and
oxidative phosphorylation of cardiac mitochondria [120].
In addition, the absence of functional ATM in the mitochon-
dria of ATM-null thymocytes and fibroblasts was associated
with decreased ATP production, increased ROS production
[24, 25], and a decrease in mitophagy [119, 123].
Therefore, activation of ATM by oxidative stress and
the consequent maintenance of redox homeostasis through
autophagy, pexophagy, aggrephagy, and mitophagy place
ATM at the centre of cross-talk between ROS and
autophagy signalling.
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